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Abstract The time-course for aging-associated
effects on vascular reactivity to U46619, a stable
analogue of thromboxane A2 (TXA2), was studied in
aorta from female senescence-accelerated mice-prone
(SAMP8), a murine model of accelerated senescence.
SAMP8 and senescence-accelerated mice-resistant
(SAMR1) were divided into three groups: 3-, 6- and
10-month-old. Contractile curves to U46619 (10−9 to
10−6 M) were performed in aortic rings in the absence
or in the presence of nitric oxide synthase (NOS)
inhibitor NG-nitro-L-arginine methyl ester (L-NAME;
10−4 M) and/or cyclooxygenase (COX) inhibitor
indomethacin (10−5 M). Protein and gene expression
for COX-1 and COX-2 were determined by immuno-
fluorescence and real-time PCR, respectively. Maxi-
mal contraction to U46619 was markedly higher in
SAMP8 at all ages. In SAMR1, increases were seen at
10 months, while SAMP8 displays augmented con-
traction at 6 months, which was further increased at
10 months. L-NAME enhanced U46619 contractions
in both 6-month-old groups, although the increase
was higher on vessels from SAMR1 at this age.
Indomethacin equally increased U46619 contractions
in both 3-month-old groups, suggesting the produc-
tion of vasodilator prostaglandin in young animals. In
contrast, at 6 and 10 months indomethacin decreased
U46619 contractions in both groups, indicating an
aging-associated swap to a release of contractile
prostanoids in aorta. In conclusion, aging enhances
contractile responses to TXA2 in aorta from female
mice by a mechanism involving a decrease of NO
production and increased action of contractile prosta-
noids. This process occurs earlier in SAMP8 mice,
establishing these mice as good model to study
cardiovascular aging in a convenient and standard
time-course.
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Introduction
Aging is a physiological process associated with
an increase in cardiovascular morbidity and
mortality, even in the absence of known cardio-
vascular risk factors (Lakatta and Levy 2003).
Throughout aging, structural and functional altera-
tions are produced in vasculature. Vascular aging is
associated with endothelial dysfunction, arterial stiff-
ening and remodeling, impaired angiogenesis, defec-
tive vascular repair, and with an increasing prevalence
of atherosclerosis (Erusalimsky 2009; Lakatta and
Levy 2003).
During their fertile life, women have a lower risk
of cardiovascular disease, as compared to their male
peers. However, this protection is lost after meno-
pause, when besides aging, a decline of sex hormones
production has been associated to increased risk of
cardiovascular disease (Kannel 2002). Unfortunately,
little information is available on the vascular effects
of aging in females.
Changes in vascular pathophysiology have been
extensively studied in mice models because their
physiological and genetic parallel with human
cardiovascular system (Paigen et al. 1994; Yutzey
and Robbins 2007). Particularly, the senescence-
accelerated mouse-prone 8 strain (SAMP8) has been
described as one of the most appropriate models to
study vascular aging and age-associated diseases
compared with the senescence-accelerated mouse-
resistant 1 (SAMR1) strain (Butterfield and Poon
2005; Miyamoto 1997). Vascular studies using these
models are not abundant, but few studies in male
(Llorens et al. 2007) and female (Novella et al. 2010)
mice have shown morphological alterations, mechan-
ical and endothelial dysfunction.
Thromboxane A2 (TXA2), a lipid mediator synthe-
sized from arachidonic acid metabolism through the
cyclooxygenase (COX) pathway, is a powerful con-
strictor of vascular smooth muscle (Narumiya et al.
1999). TXA2 is produced in far smaller quantities,
primarily by the platelets, and to a lesser extent by
some systemic blood vessels (Smith 1986). Recent
studies reveal that the TXA2 pathway is modulated by
estrogens, and therefore, may play an important role
in the regulation of vascular tone and blood pressure
in females, in both normal and in pathophysiological
states (Sellers and Stallone 2008). Constrictor prosta-
noids, such as TXA2 are known to regulate vascular
tone by increasing contractile response of the systemic
vasculature. Studies have shown that endothelium-
derived prostaglandins increase vessel tone in aged
females (Stewart et al. 2000), although few studies
have addressed to the specific role of TXA2 to
vascular aging in females.
We have recently reported vascular alterations in
middle-aged SAMP8 female mice. In this model,
aging-related changes on vascular reactivity was
associated to changes on NO and eicosanoids path-
ways (Novella et al. 2010). In this study, we aimed to
identify the time points for functional and molecular
changes in the vascular wall in response to TXA2 on
SAMP8 and SAMR1 models. For that, female mice
were studied at ages spanning from young adult to
near the mean survival.
Material and methods
Experimental animals
Female SAMR1 (n=42) and SAMP8 (n=42) were
obtained from the breeding stock at Parc Cientific de
Barcelona and housed according to institutional
guidelines (constant room temperature—22°C, 12 h
light/dark cycle, 60% humidity, standard mice chow
and water ad libitum). All protocols were approved by
the Institutional Ethics Committee at the University of
Valencia, conformed to the National Institutes of
Health Guide for the Care and Use of Laboratory
Animals. Both SAMR1 and SAMP8 mice were
euthanized under anesthesia at 3, 6, and 10 months
old for tissue harvesting.
Determination of biochemical variables
Blood samples were withdrawn by cardiac puncture and
centrifuged at 1,200×g for 10 min. Plasma levels of
glucose, creatinine, and 17β-estradiol were deter-
mined using an automatic analyzer (ADVIA Cen-
taur® CP Immunoassay System, Siemens, Munich,
Germany) at a commercial analytical service center.
The levels of NO metabolites (NO2
−/NO3
−) were
determined in the plasma by a commercial colorimetric
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assay kit (Cayman Chemical Company) following the
supplier’s instructions.
Isolated mouse aorta preparation
Thoracic aorta was excised, placed immediately in ice-
cold Krebs–Henseleit solution and cleaned of surround-
ing tissue. Arteries were dissected into 4-mm rings,
mounted between two stainless steel holders (100 μm
inner diameter), and placed in a 4 ml organ baths
containing modified Krebs–Henseleit (in mM: NaCl
115; KCl 4.6; KH2PO4 1.2; MgCl2 1.2; CaCl2 2.5;
NaHCO3 25; glucose 11.1; EDTA 0.01, pH 7.3–7.4)
kept at 37°C and aerated with 95% O2/5% CO2 for
isometric force measurements (Grass FT03, Grass
Instruments Division Astromed, Inc., West Warwick,
RI, U.S.A.). Changes in isometric force were recorded
by use of Chart v. 3.4/s software and a MacLab/8e
data acquisition system (ADInstruments, East Sus-
sex, UK). Once the optimal resting tension was
reached (1 g), aortic rings were allowed to attain a
steady level of tension during a 1-h equilibration
period before testing. Functional integrity of the
endothelium was confirmed routinely by the pres-
ence of relaxation induced by acetylcholine (10−7–
10−6 M) during contraction obtained with serotonin
(10−5 M).
In vitro tension measurement
Following the equilibration period, arterial segments
were exposed to receptor-independent depolarizing
agent KCl (60 mM) until the contraction reached a
stable plateau (10 to 20 min). After washout and
return to stable baseline, contractile responses were
determined by cumulative concentration–response
curves to KCl (5–120 mM) or the TXA2 mimetic
U46619 (10−9 to 3×10−7 M). In some experiments,
rings were incubated for 15 min with NG-nitro-L-
arginine methyl ester (L-NAME, 10−4 M), indometh-
acin (10−5 M) or the combination of L-NAME
(10−4 M) plus indomethacin (10−5 M).
Immunofluorescence
Protein expression and localization of prostaglandin-
associated enzymes COX-1 and COX-2 were deter-
mined in aortic sections from SAMR1 and SAMP8
mice by immunofluorescence as previously described
(Novella et al. 2010). Aortic sections (4 μm) were
thaw-mounted onto polylysine covered slides, fixed in
acetone (15 min) and blocked for 30 min with horse
serum. Sections were incubated overnight at 4°C with
primary antibodies: 1:200 anti-COX-1 (Santa Cruz—
sc19998) or 1:200 anti-COX-2 (Santa Cruz—
sc19999). Following washes, sections were co-
stained with 10 μM phalloidin (Sigma) and secondary
antibodies 1:500 Alexa Fluor 488 conjugated goat
anti-rabbit (Invitrogen). Coverslips were mounted on
slides using ProLong Gold antifade reagent with
DAPI (Invitrogen), and sections were visualized
through a confocal microscope (Axiovert 2000, Carl
Zeiss Inc) with a 40× objective lens (Zeiss). For each
image, light was passed through a different excitation
filter: (1) 350 nm (for DAPI); (2) 490 nm (for Alexa
488); and (3) 590 nm (for phalloidin). Each aorta was
recorded in three different regions and results were
expressed as an average of fluorescence elicited using
Mac Biophotonic ImageJ Software.
Quantitative real-time PCR
Total RNA was isolated and reverse transcribed as
previously described (Novensa et al. 2010). mRNAs
encoding COX-1 and COX-2 were quantified by
Quantitative real-time PCR (qRT-PCR) based on
SYBR® Green fluorescence, using the GAPDH
mRNA as internal control. The specific primer
sequences for mice were: COX-1 (NM_008969.3)
5′-CCA GTG CTG GGG CAG TGC TG-3′, 5′-ACA
CGG ACG CCT GTT CCA CG-3 ′ ; COX-2
(NM_011198.3) 5′-TCC GAG CTG TGC TGC TCT
GC-3′, 5′-GCC CAG TCC TCG GGT GAA CC-3′;
GAPDH (NM_008084.2) 5′-ACC CCA GCA AGG
ACA CTG AGC AAG-3′, 5′-TGG GGG TCT GGG
ATG GAA ATT GTG-3′. Real-time PCR reactions
were set following the manufacture’s conditions
(Applied Biosystems). Ct values obtained for each
gene were normalized to Ct of housekeeping gene
GAPDH (ΔCt) and converted to the linear form using
the term 2-ΔCt, and expressed as 2−ΔCt.
Drugs
The following drugs were used: serotonin hydrochlo-
ride, acetylcholine chloride, NG-nitro-L-arginine methyl
ester hydrochloride (L-NAME), indomethacin and
9,11-dideoxy-11α,9α-epoxymethanoprostaglandin
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F2α (U46619) were obtained from Sigma (Sigma
Chemical Co, St. Louis, MO, USA). All drugs for
vascular reactivity studies were dissolved in Krebs
solution except U46619, which was dissolved initially
in ethanol, and indomethacin, which was dissolved in
ethanol and sodium bicarbonate solution (150 mM)
and readjusted to pH 7.4 with HCl prior to use further
diluted in Krebs solution to the proper final concen-
tration. Stock solutions of each drug were freshly
prepared at the day of experiment, and kept on ice
throughout the experiment.
Data analysis
Data are expressed as means±SEM. Contractions to
KCl and U46619 are shown as absolute tension (in
milligrams). The pD2 (negative logarithm of the molar
concentration at which half-maximum contraction
occurs) was determined from individual concentration–
response curves by non-linear regression analysis. Area
under the concentration–response curve (AUC) was
calculated from each individual concentration–response
curve to U46619 and was expressed as arbitrary units.
The contribution of NO and prostanoids to the vascular
contraction induced by the TXA2 analogue was
calculated by subtracting from the AUC for U46619,
the AUC for U46619 in the presence of L-NAME
and/or indomethacin. In each experimental group n
indicates the number of animals. Differences between
mouse strains (i.e., SAMR1 vs. SAMP8) and by
experimental groups (i.e., 3- vs. 6- vs. 10-month-old
groups) were analyzed by two-way ANOVA, fol-
lowed by Bonferroni’s post-test to compare replicate
means. Statistical significance was accepted at P<
0.05. The statistical analysis was carried out using the
Prism 4 software (GraphPad Software Inc., San
Diego, CA, USA).
Results
Biochemical and morphological parameters
In both strains, body weight significantly increased
with age, although SAMP8 weighed much less at 6
and 10 months than SAMR1 (Table 1). Uterine
weights and estrogen levels did not differ among
groups, indicating that female mice did not change
ovarian function with aging. Besides, a trend to
increase glucose was observed and creatinine plas-
matic concentrations were not affected by aging.
Effects of age on contractile responses
Age-dependent increase of contraction in response
to KCl
Figure 1a shows concentration-dependent responses
induced by cumulative applications of KCl to aortic
rings from SAMR1 and SAMP8 groups, and
Table 2 shows the corresponding pD2 values and
maximal contractions (Emax). In aorta from 3-month-
old groups, pD2 values and maximal responses did
not differ in both SAMR1 and SAMP8 mice. Differ-
ences between strains start to appear at 6 months,
when maximal contractions in response to KCl were
Table 1 Physiological and biochemical parameters in female SAMR1 and SAMP8
SAMR1 SAMP8
3 months 6 months 10 months 3 months 6 months 10 months
Body weight (g) 23.7±0.2 26.7±0.6* 30.7±1.0*,*** 23.2±0.3 24.6±0.4*,**** 27.4±0.7*,***,****
Uterus weight (mg) 105±8 108±10 112±7 100±5 100±7 109±5
Glucose (mg/dL) 165±31 170±18 185±17 159±13 173±15 197±11
Creatinine (mg/dL) 0.29±0.01 0.27±0.01 0.26±0.02 0.29±0.02 0.28±0.01 0.30±0.02
17β-estradiol (pg/mL) 286±76 317±66 283±67 328±59 286±50 309±36
NO2
−/NO3
− (μM) 22.2±1.3 16.8±1.0 13.1±1.1** 19.1±1.7 10.5±1.6**,**** 8.3±0.4**,****
Values are means±SEM. n=10 animals per group
*P<0.05 and **P<0.01 versus 3-month-old group of the same strain, ***P<0.05 versus 6-month-old group of the same strain,
****P<0.05 versus SAMR1 with same age
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significantly enhanced in aorta from SAMP8 compared
to SAMR1, and continue increasing when mice are
10 months old. Responses at 10-month-old SAMR1
were comparable to that obtained at 6-month-old
SAMP8.
Age-dependent increase of contraction in response
to U46619
Contractile responses to the TXA2 analogue U46619
were increased in all groups of SAMP8 in comparison
to SAMR1 (Fig. 1b and Table 3), although a marked
difference on the time-course for hyper-reactivity to
TXA2 was observed when SAMR1 and SAMP8 were
compared. In SAMR1, increases on Emax and pD2
values by U46619 were only seen at 10-month-old
mice (Fig. 1b and Table 3). Conversely in SAMP8,
both Emax and pD2 values to U46619 starts to enhance
at 6-month-old group, and is further increased at
10 months of age (P<0.05; Fig. 1b and Table 3).
Effects of aging on NO contribution to vascular
function
At 3 months of age, treatment with the NOS
inhibitor L-NAME (10−4 M) similarly increased
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Fig. 1 Concentration–
response curves to a KCl
(5–120 mM) and b the
analogue of thromboxane
A2 U46619 (10
−9 to
3×10−7 M) in aortic rings
from 3-, 6-, and 10-month-
old SAMR1 and SAMP8
mice. Each data point show
mean±SEM from n=10
mice for each group
Table 2 pD2 values and maximal responses (Emax) to KCl in aortic rings from 3-, 6-, and 10-month-old groups of both SAMR1 and
SAMP8 mice
SAMR1 SAMP8
pD2 Emax pD2 Emax
3 months 1.48±0.01 620 ±15 1.48±0.01 637±21
6 months 1.44±0.01 634±25 1.45±0.02 784±38*,**
10 months 1.53±0.02**,*** 748±24**,*** 1.52±0.01**,*** 933±23*,**,***
Values are means±SEM. n=10 animals per group
*P<0.05 vs. SAMR1 group with same age, and **P<0.05 vs. 3-month-old group of the same strain, and ***P<0.05 vs. 6-month-old
group of the same strain
AGE (2013) 35:117–128 121
Emax and pD2 values to the TXA2 analogue U46619
in both SAMR1 (ΔAUC, 717±125) and SAMP8
(ΔAUC, 895±156). Differences on NO contribution
to TXA2-induced contractions were noticed at
6 months of age. Although L-NAME enhanced
U46619 contractions in both 6-month-old SAMR1
and SAMP8, the increase observed on vessels from
SAMR1 was much higher compared to SAMP8
(ΔAUC, 790±129 and 520±122, respectively). At
the age of 10 months, L-NAME treatment induced no
effects on contractions by U46619 in both SAMR1
and SAMP8 (Fig. 2 and Table 3). In support to the
data on vascular reactivity, biochemical studies reveal
an earlier and more pronounced aging-associated
decrease of NO production in SAMP8 when compared
to SAMR1. Measurement of NO metabolites NO2
−/
NO3
− in plasma samples of SAMR1 and SAMP8
mice reveals a progressive decrease on NO produc-
tion in SAMP8, while SAMR1 mice shows a
significant decrease on NO production only at age
of 10 months (Table 1).
Aging-associated effects on COX pathway
The COX inhibitor indomethacin (10−5 M) did not
change the pD2 values but significantly increased the
maximal response to U46619 in aortic rings of
both SAMR1 and SAMP8 mice at 3 months of
age, indicating the involvement of relaxing prosta-
noids as modulators of the U46619 response at
this age (Fig. 3 and Table 3). Conversely, indometh-
acin decreased the sensitivity to U46619 at 6 months,
and the sensitivity and Emax to U46619 at 10 months
(Fig. 3 and Table 3), suggesting a swap from the
contribution of relaxing prostaglandins to a higher
involvement of vasoconstrictor prostaglandins to the
modulation of vascular contraction. Analysis of gene
and endothelial protein expression of the two sub-
types of COX (COX-1 and COX-2) show an aging-
associated increase of COX-1 expression that was
evident at 10 months of age (Fig. 4a and b).
Conversely, aging did not affect COX-2 expression,
even though vessels from SAMR1 express a higher
Table 3 pD2 values and maximal responses (Emax) to U46619
in aortic rings in the absence (Control) and in the presence of L-
NAME (10−4 M), indomethacin (10−5 M) or L-NAME plus
indomethacin from 3-, 6-, and 10-month-old of both SAMR1
and SAMP8 mice groups
SAMR1 SAMP8
pD2 Emax pD2 Emax
Control
3 months 7.93±0.04 1,224±50 8.07±0.04 1,435±60*
6 months 7.92±0.09 1,230±60 8.24±0.03*,** 1,581±51*,**
10 months 8.13±0.08**,*** 1,400±44**,*** 8.30±0.08*,** 1,893±67*,**,***
L-NAME 10−4 M
3 months 8.27±0.06**** 1,496±83**** 8.30±0.05**** 1,702±99****
6 months 8.21±0.08**** 1,553±81**** 8.19±0.05 1,851±49****
10 months 8.16±0.06 1,484±54 8.26±0.05 1,876±80
Indomethacin 10−5 M
3 months 7.90±0.05 1,435±49**** 8.01±0.04 1,651±81****
6 months 7.58±0.07**,**** 1,146±77** 7.73±0.05**,**** 1,544±83
10 months 7.60±0.06**,**** 1,177±70**,**** 7.78±0.04***,**** 1,582±61****
L-NAME 10−4 M+indomethacin 10−5 M
3 months 8.02±0.02 1,578±60**** 8.12±0.05 1,839±87*,****,*****
6 months 7.67±0.03** 1,326±70 7.88±0.05***** 1,733±58*
10 months 7.76±0.04**,***** 1,493±77 8.00±0.04***** 1,888±64*,*****
Values are means±SEM. n=10 animals per group
*P<0.05 vs. SAMR1 group with same age, **P<0.05 vs. 3-month-old group of the same strain and treated group, ***P<0.05 vs.
6-month-old group of the same strain and treated group, ****P<0.05 vs. same age and strain of control group and *****P<0.05 vs.
same age and same strain indomethacin group
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level of COX-2 protein than do SAMP8 mice (Fig. 4a
and b).
Effects of both NOS- and COX- inhibition
on contractile responses to U46619
Concomitant treatment with L-NAME (10−4 M) and
indomethacin (10−5 M) did not change pD2 values,
but increased significantly the maximal response to
U46619 in aortic rings of both SAMR1 and SAMP8
mice at the age of 3 months. In the 6- and 10-month-
old groups maximal responses did not change, but
significantly decreased the pD2 values. Interestingly,
COX inhibition partially restored the increasing
effects of L-NAME on the contractile responses to
U46619 (Fig. 5 and Table 3).
Discussion
The present study brings new insights in the compre-
hension of the physiological role of aging on TXA2
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responses in aorta from female mice with accelerated
senescence. Our results indicate that aging (1) induces
an increment in contractile responses to KCl and
TXA2 analogue U46619, (2) evokes a decrease of NO
bioavailability in response to U46619, and (3) modifies
the functional prostanoids involved in the regulation of
TXA2 contraction. Although aging similarly affects
vascular function in both SAMR1 and SAMP8, those
responses were accelerated in SAMP8, establishing
this strain as an appropriate model to study vascular
effects of aging in females.
At 3 months of age, both strains exhibited a similar,
receptor-independent contractile response induced by
high extracellular concentrations of KCl, thus discard-
ing differences due to strain-specific changes. Never-
theless, at 6 months old, and even further at 10 months
old, contractile responses in SAMP8 mice were higher
than those of SAMR1. The increased contractions to
KCl in SAMP8 indicate that intrinsic mechanisms
contribute to the altered vasoconstrictor responses.
KCl-induced constriction is mediated primarily via
depolarization-induced opening of voltage-gated Ca2+
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channels and influx of extracellular Ca2+ (Hall et al.
2006). Accordingly, the ability of aging in SAMP8
mice to increase constrictor responses to KCl is
suggestive of an action on voltage-gated Ca2+
channels or distal mechanisms that respond to this
influx of Ca2+.
Examination of plasma glucose and creatinine
level, demonstrated that there were no differences
between SAMR1 and SAMP8 mice, which rules
out a possible contribution of age-induced meta-
bolic changes or impaired renal function to vaso-
motor dysfunction. Furthermore, measurements of
17β-estradiol levels did not differ between SAMR1
and SAMP8 animals at different ages, which
exclude hormonal status as an explanation for the
observed differences in vascular responses. Like
other rodents, SAM mice do not reach reproductive
senescence until later in life (Yuan et al. 2005).
According to uterine weight data and 17β-estradiol
plasma levels in SAM animals, we can suggest that, at
least until 10 months, SAMR1 and SAMP8 exhibit
similar hormonal status, confirming this hypothesis.
For this reason, the SAM model still could not be
considered, as such, as a good model to study natural
menopause, despite being a good model to study
progressive aging. In this regard, in a previous study
we have described middle-aged SAMP8 ovariecto-
mized mice as a new model to concomitantly study
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Fig. 4 Cyclooxygenase
(COX) expression in thoracic
aorta from SAMR1 and
SAMP8 female mice at
different ages: a top:
representative immunofluo-
rescent merged images of
COX-1 (left) and COX-2
(right). Staining shows
nucleus (blue, DAPI), actin
fibers (red, phalloidin),
COX (green). Bar graphs
(bottom) show the results of
densitometric analyses from
pooled data of endothelial
expression of COX-1 and
COX-2. b COX-1 (left)
and COX-2 (right) mRNA
expression in mice aorta
normalized to the expres-
sion of GAPDH, which
was used as an endogenous
reference gene. Data are
plotted as the mean±SEM
derived from four to eight
independent experiments.
*P<0.05; **P<0.01;
***P<0.001
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the effects of aging and menopause in female mice
(Novella et al. 2010).
In addition to the changes on intrinsic mechanisms to
evoke vasoconstriction by aging, SAMP8 model
reveled to be a great model to study aging-associated
modifications on signaling pathways involved in the
control of vasomotion. In our studies, we have observed
a significant aging-associated increase on vasoconstric-
tion induced by the TXA2 analogue U46619, which
was more pronounced in females with accelerated
senescence (SAMP8) than those with a normal life
span (SAMR1). The enhanced contractile responses
observed in our study to U46619 were associated to a
decrease of vasodilators and/or an increase of vaso-
constrictors. Our data suggest that increase in the
release of NO and vasodilator prostaglandins in
response to TXA2 receptor activation may contribute
to a lower contractile response in young females,
since both NOS inhibitor (L-NAME) and the COX
inhibitor (indomethacin) augmented contractile
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Fig. 5 a Concentration–re-
sponse curves to U46619 in
aortic rings from 3-, 6-, and
10-month-old SAMR1 and
SAMP8 mice in the absence
(Control) and in the pres-
ence of L-NAME (10−4 M)
plus indomethacin (Indo.
10−5 M). b Area under
curves (AUC) from concen-
tration–response curves in
absence (control) minus
AUC in the presence of
L-NAME (10−4 M) plus
Indo. (10−5 M). Each data
point show mean±SEM
from n=10 mice for each
group. *P<0.05 vs.
3-month-old group of the
same strain and treated
group, #P<0.05 vs.
6-month-old group of the
same strain, and †P<0.05
vs. SAMR1 group with
same age. Each data point
show mean±SEM from
n=10 mice for each group
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responses in aorta from mice at 3 month of age. The
increased contractions induced by L-NAME were
reduced with aging in both SAMR1 and SAMP8
mice, suggesting a decrease of NO bioavailability by
aging. Besides, our measurement of plasmatic con-
centration of NO metabolites NO2
−/NO3
− revealed an
aging-associated decrease on NO concentration.
These findings are consistent with previous observa-
tions of aging-related decline in NO bioavailability
(Collins and Tzima 2011; Taddei et al. 1995; 1997).
Nevertheless these effects were observed before in
SAMP8 (at 6 months) than in SAMR1 (only at
10 months), suggesting that a decrease of NO
bioavailability by aging starts earlier in our model of
accelerated senescence. Contrary to our data, an age-
related increase of NOS activity without changes in
NO levels has been described in cerebral cortex of
SAMP8 mice (Inada et al. 1996). The increased NOS
activity observed in the brain may be associated to
increased mRNA expression of the neuronal isoform
of NOS (nNOS) (Colas et al. 2006). In aortas from
6-month-old male mice, where endothelial NOS
(eNOS) is the predominant isoform, both SAMR1
and SAMP8 showed similar eNOS immunoreactivity,
suggesting that decreased NO bioavailability might
not be related to changes in eNOS protein expression
in SAMP8 (Llorens et al. 2007).
Regarding to prostaglandin production by U46619,
contractions induced by this agonist were interesting-
ly attenuated by the nonselective COX inhibitor
(indomethacin) at 6 and 10 months, suggesting a
higher production of vasoconstrictor prostanoids.
With aging, along with a further impairment of L-
arginine–NO pathway, COX-dependent vasoconstric-
tors production becomes evident (Rodriguez-Manas et
al. 2009; Taddei et al. 1997). This is supported to the
fact that aspirin (a well-known COX inhibitor) is
routinely prescribed to patients with vascular disease.
Furthermore, Aspirin use has been associated with
significantly lower risk of all-cause mortality, and
more specifically, cardiovascular mortality, among
women with stable cardiovascular disease (Berger
et al. 2009). Moreover, older women were noted to
have the greatest benefit with aspirin therapy, a
finding consistent with the Women’s Health Initiative
study (Ridker et al. 2005). Since stimulation or
upregulation of COX is able to produce vasodilator
and vasoconstrictor products, our results in aorta from
SAM mice interestingly demonstrate that aging is
associated with a shift towards vasoconstrictor
products.
Agonist-induced activation of the arachidonic acid
cascade leads to the production of both vasodilator and
vasoconstrictor prostaglandins by the endothelium, and
how distinct pathophysiological conditions affect the
equilibrium of prostaglandin release in either direction is
largely unknown. In our studies, we attempt to
determine if changes on COX-1/COX-2 expression
could account to the swap on prostaglandin release
during aging. Our data show a significant increase
of both gene and protein expression of COX-1,
although this increase does not explain the shift on
prostaglandin-mediated responses since it was seen
only when mice were 10 months old. In previous
studies, we have demonstrated an increased con-
traction to U46619 in association with TXA2
receptor expression in 6-month-old SAMP8 female
aorta compared with age-matched SAMR1 (Novella
et al. 2010). In corroboration with our studies is an
observation that augmented prostanoid-dependent
vasoconstriction in other pathophysiological condi-
tion (i.e., obesity) is associated to increased TXA2
receptor gene expression rather than change of
prostaglandin metabolism (Traupe et al. 2002).
One of the trickiest parts in the field concerns to
the selection of the most appropriate age to investi-
gate mechanisms involved in vascular aging when we
use rodent models. Most studies have been done in
mice on the verge of senescence and thus were unable
to correlate vascular alterations that may occur during
the aging process or at early stages of aging, when
cardiovascular damage starts. Our functional and
molecular analyses in SAMR1 and SAMP8 mice
indicate that contractile responses are similar or
slightly enhanced between young mice at 3 months
of age, but become statistically different by 6 months
and continue to change thereafter. This should be
considered when selecting the most appropriate time
points for investigating the mechanisms mediating
vascular aging.
Our results demonstrated that contractile response
to TXA2 is increased with aging by a mechanism
involving the decreased bioactivity of NO and
increased production of contractile prostanoids. The
inhibition of COX induces an increase of NO
bioavailability. These effects occur earlier in aorta
from female SAMP8 mice and are manifest at
6-month-old mice, establishing SAMP8 mice as a
AGE (2013) 35:117–128 127
good model to study cardiovascular aging in a
convenient and standard time-course.
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